ELISA/assay

Cetuximab (Erbutrix) PK

MBS378001

1 x96 Wells

625 USD

ELISA Kit

Cetuximab (Erbutrix) PK

Cetuximab (Erbutrix) PK

Shelf life: 6 months from date of shipment.

Samples: Serum and plasma. Assay Type: Sandwich

Principle of the Assay This assay employs the sandwich enzyme immunoassay technique. Anti- Cetuximab is coated onto a 96 well microplate. Calibrator, quality control samples (if desired) and test samples are pipetted into the appropriate wells. Cetuximab present in biological matrices is bound by the immobilized anti- Cetuximab antibody. After washing away any unbound substances, enzyme linked anti- Cetuximab antibody is added to the wells. This antibody is developed and purified specifically against truncated Erbitux (domain residing in Fc portion of the Erbitux molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Cetuximab present in test samples. The color development is stopped and the intensity of the color is measured. Background/Introduction: Cetuximab (Erbitux) is a chimeric IgG1 monoclonal antibody that binds the extra-cellular domain of the epidermal growth factor receptor (EGFR). It is a 152-kDa molecule composed of four polypeptide chains: two identical heavy chains and two identical light chains, consisting of 449 and 214 amino acids, respectively, bound by covalent and non- ovalent bonds. The bond with EGFR is characterized by a higher affinity than either endogenous ligand, as epidermal growth factor (EGF), or transforming growth factor alpha. This binding inhibits activation of the receptor tyrosine kinase and the associated downstream signaling that includes the mitogen-activated protein kinase, phosphoinositide 3-kinase/Akt and the Janus kinases/ signal transducers and activator of transcription (Stat) pathways. Furthermore Cetuximab induces antibody-mediated receptor dimerization, internalization and degradation leading to receptor down-regulation. In addition, it exhibits antibody-dependent cellular cytotoxicity that could contribute to its antitumor effect. Cetuximab has a long elimination half-life with values ranging from 70 to 100 hours at the target dose. Cetuximab serum concentrations reached stable levels after three weeks of Cetuximab monotherapy. Mean peak Cetuximab concentrations were 155.8 ug/mL in week 3 and 151.6 ug/mL in week 8, whereas the corresponding mean trough concentrations were 41.3 and 55.4 ug/mL, respectively. In a study of Cetuximab administered in combination with irinotecan, the mean Cetuximab trough levels were 50.0 ug/mL in week 12 and 49.4 ug/mL in week 36. The current research effort towards the development of biosimilars and therapeutic agents for second-generation treatment of colorectal cancer in combination with Cetuximab requires a selective and sensitive bioanalytical method. The AffinityImmuno Cetuximab ELISA kit is designed to measure Cetuximab with high specificity and enhanced sensitivity in serum or plasma. This user-friendly assay design utilizes a monoclonal antibody to capture Cetuximab to the plate and

1 x96 Wells

625 USD